AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02860949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)
Study NCT02860949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL
Study NCT00978159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole 20 mg po for 4 weeks
Study NCT00978159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40 mg po for 4 weeks
Study NCT01844401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax®
Description: Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
Study NCT01844401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAir® HFA
Description: ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
Study NCT03351504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar lighting system
Description: consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
Study NCT03398980 — intervention group
Intervention type: RADIATION
Intervention: survivors treated with CRT
Description: Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
Study NCT03950661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Study NCT04053699 — intervention group
Intervention type: DRUG
Intervention: Von Willebrand Factor-Containing Product
Description: Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
Study NCT03656198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabivax-S
Description: Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
Study NCT03656198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water Injection
Description: The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
Study NCT02056847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin calcium 4mg
Description: taking once a day
Study NCT02056847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin calcium 2mg
Description: Taking once a day
Study NCT03031509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Epithelial Cells
Description: Human Amniotic Epithelial Cells transplant after debridement
Study NCT03476161 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214
Description: One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
Study NCT03075124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counter Pulsation
Description: A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
Study NCT04475484 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire
Description: Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress.
Study NCT02994368 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT03031509 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: debridement
Description: debridement
Study NCT03031509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement
Description: debridement
Study NCT00797550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Repair Cells (BRCs)
Description: BRCs will be administered during spine fusion surgery
Study NCT00797550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Study NCT02614157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLND
Description: advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
Study NCT02614157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: labeled line
Study NCT01335061 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nonacog alfa
Description: Period 1: During on-demand period, dosing at the discretion of investigator.
Study NCT01335061 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nonacog alfa
Description: Period 2: During the prophylaxis period, 100 IU/kg once weekly
Study NCT02315118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-cell therapy + Rituximab + IL-2
Description: * T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients
Study NCT00444743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MM-093
Description: 60 mg, administered subcutaneously, weekly
Study NCT00444743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02022293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients in this group will take 20mg per night.
Study NCT02022293 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04130490 — intervention group
Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
Study NCT02086461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic pyloric dilatation
Study NCT02086461 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 15 mm pyloric balloon dilatation
Study NCT04082598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
Study NCT04082598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum and Lactoferrin
Study NCT01965990 — intervention group
Intervention type: OTHER
Intervention: NEP
Description: A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
Study NCT01208506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
Study NCT04194645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study NCT04194645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution
Study NCT04194645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Placebo solution
Study NCT01573299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization of stroke patients
Description: In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset.
Study NCT01208506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
Study NCT02925039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehab with computer feedback
Description: Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
Study NCT02925039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT01208506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
Study NCT01208506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
Study NCT01208506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
Study NCT01208506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.
Study NCT01700231 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection of patient with neoplastic hepatic tumors
Study NCT05019443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wedge Scoring Balloon
Description: Scoring balloon
Study NCT05019443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon
Description: Conventional balloon
Study NCT01611779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encore Tongue Suspension System
Description: The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
Study NCT00940485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5mg po daily for 8 weeks
Study NCT00940485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: 0.5mg po daily for 48 weeks
Study NCT01402674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abrupt cessation of phentermine pharmacotherapy
Description: Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
Study NCT02965274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Fluoxetine Tablets
Study NCT02965274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warner Chilcott LLC's Sarafem Tablet
Study NCT06029634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-bet B cell
Description: The frequency, function, and phenotype of T-bet B cells was tested
Study NCT00940485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week for 48 weeks
Study NCT03826680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible fiberoptic laryngoscopy
Description: Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
Study NCT03826680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
Study NCT05978635 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group A Standard 4 deep breaths measured in milliliters from the ventilator.
Description: Tidal volume breath measured in milliliters
Study NCT05978635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group B Coached 4 deep breaths measured in milliliters from the ventilator
Description: Coached tidal volume breath measured in milliliters
Study NCT01114360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
Study NCT02940431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Autonomy
Description: Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
Study NCT02940431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Autonomy
Description: Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
Study NCT01118975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off.
Study NCT01118975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1,250 mg once daily
Study NCT04514432 — intervention group
Intervention type: OTHER
Intervention: Music
Description: If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
Study NCT01013662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glycemic control
Description: exogenous insulin
Study NCT02784041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single adductor-canal-block
Description: Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
Study NCT02784041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: periarticular infiltration
Description: The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
Study NCT03149276 — intervention group
Intervention type: OTHER
Intervention: Interpreter services
Study NCT02442180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (Filgrastim injection)
Description: G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
Study NCT02442180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid
Description: oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
Study NCT02442180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: steroid
Description: oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
Study NCT02442180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: equivalent to G-CSF doses
Study NCT01563497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Oral dispersion TS formulation- fasted
Study NCT01563497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Tablets TS formulation- fasted
Study NCT01563497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Tablets TS formulation- fed
Study NCT02436226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and Human chorionic gonadotropin (HCG)
Description: Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
Study NCT02436226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
Study NCT02914353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP=7041
Description: Factor X!a Inhibitor
Study NCT02914353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT03561324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging Beta Probe (IBP)
Description: Using IBP for imaging of PET positive lymph nodes
Study NCT02587065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a
Description: 125 mcg administered subcutaneously (SC) every 2 weeks.
Study NCT01114360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
Study NCT01114360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
Study NCT01114360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
Study NCT06351709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
Study NCT06351709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot pack application
Description: Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.